Valeant to buy orphan drug developer Aton for $318M #ucb #pharma #inc

Posted On Dec 6 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Aton Pharma introduces authorized generic version of Timoptic-XE #pharmaceutical #business #plan

Posted On Nov 17 2017 by

#aton pharma # Aton Pharma introduces authorized generic version of Timoptic-XE Published on March 9, 2010 at 11:43 PM Aton Pharma, Inc. a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE. Authorized generics are a very effective sales strategy for Aton Pharma’s product portfolio, stated Michael G. Wells, Chief …


Valeant to buy orphan drug developer Aton for $318M #china #pharma

Posted On Nov 17 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Suberanilohydroxamic acid aton pharma #pharmaceutical #business #plan

Posted On Sep 20 2017 by

#aton pharma # Suberanilohydroxamic acid aton pharma Citations Citations 5 References References 31 It was reported that HDACi have multiple targets involved in RA. HDACi reduce the expression of some proinflammatory cytokines, especially TNF-a and IL-1 (Leoni et al. 2002; Chung et al. 2003; Johnstone, 2004; Nishida et al. 2004; Blanchard and Chipoy, 2005; Leoni et al. 2005); induce growth arrest and/or apoptosis of the transformed RA synovial cells through the upregulation of the cell-cycle inhibitor p21 (Waf/Cip1) (Chung et al. 2003; Nishida et al. 2004; Jungel et al. 2006); inhibit angiogenesis (Deroanne et al. 2002; Mie Lee et al. …


Valeant to buy orphan drug developer Aton for $318M #usv #pharma

Posted On Aug 31 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #what #is #big #pharma

Posted On Aug 20 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #mankind #pharma

Posted On Aug 11 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Aton Pharma introduces authorized generic version of Timoptic-XE #raptor #pharma

Posted On Aug 5 2017 by

#aton pharma # Aton Pharma introduces authorized generic version of Timoptic-XE Published on March 9, 2010 at 11:43 PM Aton Pharma, Inc. a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE. Authorized generics are a very effective sales strategy for Aton Pharma’s product portfolio, stated Michael G. Wells, Chief …


Valeant to buy orphan drug developer Aton for $318M #pharma #resumes

Posted On Aug 4 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Aton Pharma Acquires U #sun #pharma #india

Posted On Jul 12 2017 by

#aton pharma # Aton Pharma Acquires U.S. TIMOPTIC(R) LAWRENCEVILLE, N.J. Feb. 25 /PRNewswire/ — Aton Pharma, Inc. a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck Co. Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma. The U.S. TIMOPTIC product line includes TIMOPTIC(R) (timolol maleate) Ophthalmic Solution, TIMOPTIC (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) and …